Major Differences between Tumor and Normal Human Cell Fates after Exposure to Chemotherapeutic Monofunctional Alkylator

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Gupte, Maithili ^b   Tuck, Andrew N ^c   Sharma, Vishal P ^d   Williams, Kandace J ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b AMGEN INC   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d BOWLING GREEN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; APOPTOSIS INDUCING FACTOR; CASPASE;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL AGING; CELL CYCLE; CELL FATE; CELL METABOLISM; CELL PROLIFERATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EXPOSURE; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; SENESCENCE; UTERINE CERVIX CARCINOMA;

ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS INDUCING FACTOR; CELL CYCLE; CELL LINE; CELL LINE, TUMOR; CELL LINEAGE; DACARBAZINE; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; METHYLNITRONITROSOGUANIDINE; NEOPLASM PROTEINS; NEOPLASMS;

EID: 84883382732     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074071     Document Type: Article

References (65)

1. Arko L, Katsyv I, Park GE, Luan WP, Park JK, (2010) Experimental approaches for the treatment of malignant gliomas. Pharmacol Therapeutics 128: 1-36. doi:10.1016/j.pharmthera.2010.04.015. PubMed: 20546782.
2. Bartek JJ, Ng K, Bartek J, Fischer W, Carter B, et al. (2012) Key concepts in glioblastoma therapy. J Neurol Neurosurg, Psychiatry 83: 753-760. doi:10.1136/jnnp-2011-300709. PubMed: 22396442.
3. Newlands ES, Stevens MFG, Wedge SR, Wheelhouse RT, Brock C, (1997) Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 23: 35-61. doi:10.1016/S0305-7372(97)90019-0. PubMed: 9189180.
4. Reid JM, Stevens DC, Rubin J, Ames MM, (1997) Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer. Clin Cancer Res 3: 2392-2398. PubMed: 9815639.
5. Gerson SL, (2004) MGMT: it's role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 4: 296-307. doi:10.1038/nrc1319. PubMed: 15057289.
6. Gladson CL, Prayson RA, Liu WM, (2010) The pathobiology of glioma tumors. Annu. Rev Pathol Mech Dis 5: 33-50. doi:10.1146/annurev-pathol-121808-102109.
7. Margison GP, Povey AC, Kaina B, Koref M, (2003) Variability and regulation of O6-alkylguanine-DNA alkyltransferase. Carcinogenesis 24: 625-635. doi:10.1093/carcin/bgg005. PubMed: 12727789.
8. Sharma S, Salehi F, Scheithauer BW, Rotondo F, Syro LV, et al. (2009) Role of MGMT in Tumor Development, Progression, Diagnosis, Treatment and Prognosis. Anticancer Res 29: 3759-3768. PubMed: 19846906.
9. Alvino E, Castiglia D, Caporali S, Pepponi R, Caporaso P, et al. (2006) A single cycle of treatment with temozolomide, alone or combined with O6-methylguanine-DNA methyltransferase and the mismatch repair system. Int J Oncol 29: 785-797. PubMed: 16964376.
10. Bignami M, O'Driscoll M, Aquilina G, Karran P, (2000) Unmasking a killer: DNA O(6)-methylguanine and the cytotoxicity of methylating agents. Mutat Res 462: 71-82. doi:10.1016/S1383-5742(00)00016-8. PubMed: 10767619.
11. Choi J-Y, Chowdhury G, Zang H, Angel KC, Vu CC, et al. (2006) Translesion Synthesis across O6-Alkylguanine DNA Adducts by Recombinant Human DNA Polymerases. J Biol Chem 281: 38244-38256. doi:10.1074/jbc.M608369200. PubMed: 17050527.
12. Yoshioka K-I, Yoshioka Y, Hsieh P, (2006) ATR kinase activation mediated by MutSα and MutLα in response to cytotoxic O6-methylguanine adducts. Mol Cell 22: 501-510. doi:10.1016/j.molcel.2006.04.023. PubMed: 16713580.
13. York SJ, Modrich P, (2006) Mismatch Repair-dependent Iterative Excision at Irreparable O6Methylguanine Lesions in Human Nuclear Extracts. J Biol Chem 281: 22674-22683. doi:10.1074/jbc.M603667200. PubMed: 16772289.
14. Wang Y, Qin J, (2003) MSH2 and ATR form a signaling module and regulate two branches of the damage response to DNA methylation. Proc Natl Acad Sci U S A 100: 15387-15392. doi:10.1073/pnas.2536810100. PubMed: 14657349.
15. Lin DP, Wang Y, Scherer SJ, Clark AB, Yang K, et al. (2004) An Msh2 Point Mutation Uncouples DNA Mismatch Repair and Apoptosis. Cancer Res 64: 517-522. doi:10.1158/0008-5472.CAN-03-2957. PubMed: 14744764.
16. Yang G, Scherer SJ, Shell SS, Yang K, Kim M, et al. (2004) Dominant effects of an Msh6 missense mutation on DNA repair and cancer susceptibility. Cancer Cell 6: 139-150. doi:10.1016/j.ccr.2004.06.024. PubMed: 15324697.
17. Liu Y, Fang Y, Shao H, Lindsey-Boltz LA, Sancar A, et al. (2010) Interactions of Human Mismatch Repair Proteins MutSa and MutLa with Proteins of the ATR-Chk1 Pathway. J Biol Chem 285: 5974-5982. doi:10.1074/jbc.M109.076109. PubMed: 20029092.
18. Jascur T, Fotedar R, Greene S, Hotchkiss E, Boland CR, (2011) N-Methyl-N'-nitro-N'-nitrosoguanidine (MNNG) triggers MSH2 and Cdt2 protein-dependent degradation of the cell cycle and mismatch repair (MMR) inhibitor protein p21-Waf1/Cip1. J Biol Chem 286: 29531-29539. doi:10.1074/jbc.M111.221341. PubMed: 21725088.
19. Pabla N, Ma Z, McIlhatton MA, Fishel R, Dong Z, (2011) hMSH2 recruits ATR to DNA damage sites for activation during DNA damage-induced apoptosis. J Biol Chem 286: 10411-10418. doi:10.1074/jbc.M110.210989. PubMed: 21285353.
20. Genschel J, Modrich P, (2009) Functions of MutLa, RPA, and HMGB1 in 5'-directed mismatch repair. J Biol Chem 284: 21536-21544. doi:10.1074/jbc.M109.021287. PubMed: 19515846.
21. Dai Y, Grant S, (2010) New insights into checkpoint kinase 1 in the DNA damage response signaling nework. Clin Cancer Res 16: 376-383. doi:10.1158/1078-0432.CCR-09-1029. PubMed: 20068082.
22. Stojic L, Mojas N, Cejka P, di Pietro M, Ferrari S, et al. (2004) Mismatch repair-dependent G2 checkpoint induced by low doses of SN1 type methylating agents requires the ATR kinase. Genes Dev 18: 1331-1344. doi:10.1101/gad.294404. PubMed: 15175264.
23. Lalezari S, Chou AP, Tran A, Solis OE, Khanlou N, et al. (2013) Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. Neuro-Oncology.
24. Hawn MT, Umar A, Carethers JM, Marra G, Kunkel TA, et al. (1995) Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. Cancer Res 55: 3721-3725. PubMed: 7641183.
25. Umar A, Koi M, Risinger JI, Glaab WE, Tindall KR, et al. (1997) Correction of hypermutability, N-methyl-N'-nitro-N-nitrosoguanidine resistance, and defective DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSH2 and MSH6. Cancer Res 57: 3949-3955. PubMed: 9307278.
26. Cahill DP, Levine KK, Betensky RA, Codd PJ, Romany CA, et al. (2007) Loss of mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res 13: 2038-2045. doi:10.1158/1078-0432.CCR-06-2149. PubMed: 17404084.
27. Hunter C, Smith R, Cahill DP, Stephens P, Stevens C, et al. (2006) A Hypermutation Phenotype and Somatic MSH6 Mutations in Recurrent Human Malignant Gliomas after Alkylator Chemotherapy. Cancer Res 66: 3987-3991. doi:10.1158/0008-5472.CAN-06-0127. PubMed: 16618716.
28. Yip S, Miao J, Cahill DC, Iafrate AJ, Aldape K, et al. (2009) MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance. Clin Cancer Res 15: 4622-4629. doi:10.1158/1078-0432.CCR-08-3012. PubMed: 19584161.
29. Bernardes de Jesus B, Blasco MA, (2012) Assessing cell and organ senescence biomarkers. Circ Res 111: 97-109. doi:10.1161/CIRCRESAHA.111.247866. PubMed: 22723221.
30. Campisi J, (2011) Cellular senescence: putting the paradoxes in perspective. Curr Opin Genet Dev 21: 107-112. doi:10.1016/j.gde.2010.10.005. PubMed: 21093253.
31. Fumagalli M, Rossiello F, Clerici M, Barozzi S, Cittaro D, et al. (2012) Telomeric DNA damage is irreparable and causes persistent DNA-damage-response activation. Nat Cell Biol 14: 355-365. doi:10.1038/ncb2466. PubMed: 22426077.
32. Yasaei H, Gilham E, Pickles JC, Roberts TP, O'Donovan M, et al. (2012) Carcinogen-specific mutational and epigenetic alterations in INK4A, INK4B and p53 tumour-suppressor genes drive induced senescence bypass in normal diploid mammalian cells. Oncogene 32: 171-179. PubMed: 22410783.
33. Chen Z, Trotman LC, Shaffer D, Lin H-K, Dotan ZA, et al. (2005) Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436: 725-730. doi:10.1038/nature03918. PubMed: 16079851.
34. Kuilman T, Michaloglou C, Mooi WJ, Peeper DS, (2010) The essence of senescence. Genes Dev 24: 2463-2479. PubMed: 21078816.
35. Ohtani N, Yamakoshi K, Takahashi A, Hara E, (2004) The p16INK4a-RB pathway: molecular link between cellular senescence and tumor suppression. J Med Invest 51: 146-153. doi:10.2152/jmi.51.146. PubMed: 15460900.
36. Kroemer G, Galluzzi L, Brenner C, (2007) Mitochondrial Membrane Permeabilization in Cell Death. Physiol Rev 87: 99-163. doi:10.1152/physrev.00013.2006. PubMed: 17237344.
37. Sevrioukova IF, (2011) Apoptosis-Inducing Factor: Structure, Function, and Redox Regulation. Antioxid Redox Signal 14: 2545-2578. doi:10.1089/ars.2010.3445. PubMed: 20868295.
38. Tait SWG, Parsons MJ, Llambi F, Bouchier-Hayes L, Connell S, et al. (2010) Resistance to caspase-independent cell death requires persistence of intact mitochondria. Dev Cell 18: 802-813. doi:10.1016/j.devcel.2010.03.014. PubMed: 20493813.
39. Otera H, Ohsakaya S, Nagaura Z-I, Ishihara N, Mihara K, (2005) Export of mitochondrial AIF in response to proapoptotic stimuli depends on processing at the intermembrane space. EMBO J 24: 1375-1386. doi:10.1038/sj.emboj.7600614. PubMed: 15775970.
40. Hangen E, Blomgren K, Bénit P, Kroemer G, Modjtahedi N, (2010) Life with or without AIF. Trends Biochem Sci 35: 278-287. doi:10.1016/j.tibs.2009.12.008. PubMed: 20138767.
41. Bhakat KK, Mitra S, (2003) CpG methylation-dependent repression of the human 0 6-methylguanine-DNA methyltransferase gene linked to chromatin structure alteration. Carcinogenesis 24: 1337-1345. doi:10.1093/carcin/bgg086. PubMed: 12807730.
42. Overmeyer JH, Yound A, Bhanot H, Maltese WA, (2011) A chalcone-related small molecule that induces methuosis, a novel form of non-apoptotic cell death, in glioblastoma cells. Mol Cancer 10: 69. doi:10.1186/1476-4598-10-69. PubMed: 21639944.
43. Schroering AG, Kothandapani A, Patrick SM, Kaliyaperumal S, Sharma VP, et al. (2009) Prolonged cell cycle response of HeLa cells to low-level alkylation exposure. Cancer Res 69: 6307-6314. doi:10.1158/0008-5472.CAN-09-0899. PubMed: 19638578.
44. Dimri GM, Lee X, Basile G, Acosta M, Scott G, et al. (1995) A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 92: 9363-9367. doi:10.1073/pnas.92.20.9363. PubMed: 7568133.
45. Schroering AG, Edelbrock MA, Richards TJ, Williams KJ, (2007) The cell cycle and DNA mismatch repair. Exp Cell Res 313: 292-304. PubMed: 17157834.
46. Schroering AG, Williams KJ, (2008) Rapid induction of chromatin-associated DNA mismatch repair proteins after MNNG treatment. DNA Repair 7: 951-969. doi:10.1016/j.dnarep.2008.03.023. PubMed: 18468964.
47. Glaab WE, Tindall KR, (1997) Mutation rate at the hprt locus in human cancer cell lines with specific mismatch repair-gene defects. Carcinogenesis 18: 1-8. doi:10.1002/(SICI)1098-2744(199701)18:1. PubMed: 9054582.
48. Lea JS, Sunaga N, Sato M, Kalahasti G, Miller DS, et al. (2007) Silencing of HPV 18 Oncoproteins With RNA Interference Causes Growth Inhibition of Cervical Cancer Cells. Reprod Sci 14: 20-28. doi:10.1177/1933719107311464. PubMed: 17636212.
49. Van Meir EG, Kikuchi T, Tada M, Li H, Diserens A-C, et al. (1994) Analysis of the p53 Gene and Its Expression in Human Glioblastoma Cells. Cancer Res 54: 649-652. PubMed: 8306326.
50. Yu S-W, Andrabi SA, Wang H, Kim NS, Poirier GG, et al. (2006) Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death. Proc Natl Acad Sci USA 103: 18314-18319. doi:10.1073/pnas.0606528103. PubMed: 17116881.
51. Ekert PG, Read SH, Silke J, Marsden VS, Kaufmann H, et al. (2004) Apaf-1 and caspase-9 accelerate apoptosis, but do not determine whether factor-deprived or drug-treated cells die. J Cell Biol 165: 835-842. doi:10.1083/jcb.200312031. PubMed: 15210730.
52. Meads MB, Gatenby RA, Dalton WS, (2009) Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer 9: 665-674. doi:10.1038/nrc2714. PubMed: 19693095.
53. Auger N, Thillet J, Wanherdrick K, Idbaih A, Legrier M-E, et al. (2006) Genetic alterations associated with acquired temozolomide resistance in SNB-19, a human glioma cell line. Mol Cancer Ther 5: 2182-2192. doi:10.1158/1535-7163.MCT-05-0428. PubMed: 16985051.
54. Happold C, Roth P, Wick W, Schmidt N, Florea A-M, et al. (2012) Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. J Neurochem, 122: 444-55. PubMed: 22564186.
55. Martin SA, Lord CJ, Ashworth A, (2010) Therapeutic Targeting of the DNA Mismatch Repair Pathway. Clin Cancer Res 16: 5107-5113. doi:10.1158/1078-0432.CCR-10-0821. PubMed: 20823149.
56. Casorelli I, Bossa C, Bignami M, (2012) DNA Damage and Repair in Human Cancer: Molecular Mechanisms and Contribution to Therapy-Related Leukemias. Int J Environ Res Public Health 9: 2636-2657. doi:10.3390/ijerph9082636. PubMed: 23066388.
57. Borovski T, Beke P, van Tellingen O, Rodermond HM, Verhoeff JJ, et al. (2013) Therapy-resistant tumor microvascular endothelial cells conribute to treatment failure in glioblastoma multiforme. Oncogene 32: 1539-1548. doi:10.1038/onc.2012.172. PubMed: 22614016.
58. Mo W, Zhang J-T, (2012) Human ABCG2: structure, function, and its role in multidrug resistance. Int J Biochem Mol Biol 3: 1-27. PubMed: 22509477.
59. Friedman HS, Kerby T, Calvert H, (2000) Temozolomide and treatment of malignant glioma. Clin Cancer Res 6: 2585-2597. PubMed: 10914698.
60. Do K, Chen AP, (2013) Molecular Pathways: Targeting PARP in Cancer Treatment. Clin Cancer Res 19: 977-984. doi:10.1158/1078-0432.CCR-12-0163. PubMed: 23269547.
61. Fojo T, Bates S, (2013) Mechanisms of resistance to PARP inhibitors- three and counting. Cancer Discov, 3: 20-23. PubMed: 23319766.
62. Clarke MJ, Mulligan EA, Grogan PT, Mladek AC, Carlson BL, et al. (2009) Effective sensitization by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines. Mol Cancer Ther 8: 407-414. doi:10.1158/1535-7163.MCT-08-0854. PubMed: 19174557.
63. Horton JK, Wilson SH, (2013) Predicting Enhanced Cell Killing through PARP Inhibition. Mol Cancer Res 11: 13-18. doi:10.1158/1541-7786.MCR-12-0512. PubMed: 23193155.
64. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG, (2010) PARP inhibition: PARP1 and beyond. Nat Rev Cancer 10: 293-301. doi:10.1038/nrc2812. PubMed: 20200537.
65. Wang Y, Kim NS, Haince J-F, Kang HC, David KK, et al. (2011) Poly(ADP-Ribose) (PAR) binding to apoptosis-inducing factor is critical for PAR Polymerase-1-dependent cell death (parthanatos). Sciencesignaling 4: 1-13. PubMed: 21467298.